REFERENCES
1. Rueff J, Rodrigues AS. Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint. Methods Mol Biol 2016;1395:1-18.
2. Pathania S, Bhatia R, Baldi A, Singh R, Rawal RK. Drug metabolizing enzymes and their inhibitors’ role in cancer resistance. Biomed Pharmacother 2018;105:53-65.
3. Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008;259:1-15.
4. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18:452-64.
5. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-4.
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
7. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75:855-62.
8. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev 2012;21:1236-43.
9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9.
10. Fojo T. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007;10:59-67.
11. Ikemura K, Iwamoto T, Okuda M. MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. Pharmacol Ther 2014;143:217-24.
12. McKenna LB, Schug J, Vourekas A, McKenna JB, Bramswig NC, et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010;139:1654-1664.e1.
13. Dalmasso G, Nguyen HTT, Yan Y, Laroui H, Charania MA, et al. MicroRNA-92b regulates expression of the oligopeptide transporter PepT1 in intestinal epithelial cells. Am J Physiol - Gastrointest Liver Physiol 2011;300:G52-9.
14. Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b Contribute to Pancreatic -Cell-Specific Silencing of Monocarboxylate Transporter 1 (Mct1). Mol Cell Biol 2011;31:3182-94.
15. Zhang JX, Xu Y, Gao Y, Chen C, Zheng ZS, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer 2017;16:18.
16. Hao G jun, Ding Y hui, Wen H, Li X feng, Zhang W, et al. Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem Biophys Res Commun 2017;488:501-8.
17. Li P, Yang X, Cheng Y, Zhang X, Yang C, et al. MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. Cell Physiol Biochem 2017;41:921-32.
18. Annalora AJ, Marcus CB, Iversen PL. Alternative splicing in the cytochrome P450 superfamily expands protein diversity to augment gene function and redirect human drug metabolism. Drug Metab Dispos 2017;45:375-89.
19. Kim SM, Wang YQ, Nabavi N, Liu Y, Correia MA. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Drug Metab Rev 2016;48:405-33.
20. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007;47:566-78.
21. Dluzen DF, Lazarus P. MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. Drug Metab Rev 2015;47:320-34.
22. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25:1679-91.
23. Rendic S, Guengerich FP. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol 2015;28:38-42.
24. Bu Z Bin, Ye M, Cheng Y, Wu WZ. Four polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene and lung cancer risk: A meta-analysis. Asian Pacific J Cancer Prev 2014;15:5673-9.
25. Elfaki I, Mir R, Almutairi FM, Abu Duhier FM. Cytochrome P450: Polymorphisms and roles in cancer, diabetes and atherosclerosis. Asian Pac J Cancer P 2018;19:2057-70.
26. Chen Y, Zeng L, Wang Y, Tolleson WH, Knox B, et al. The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. Biochem Pharmacol 2017;145:178-91.
27. Shimada T. Inhibition of carcinogen-activating cytochrome P450 enzymes by xenobiotic chemicals in relation to antimutagenicity and anticarcinogenicity. Toxicol Res 2017;33:79-96.
28. Blackburn HL, Ellsworth DL, Shriver CD, Ellsworth RE. Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Cause Control 2015;26:319-32.
29. Economopoulos KP, Sergentanis TN. Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;122:545-51.
30. Yin J, Sheng B, Qiu Y, Yang K, Xiao W, et al. Role of AhR in positive regulation of cell proliferation and survival. Cell Proliferat 2016;49:554-60.
31. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006;66:9090-8.
32. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002;30:869-74.
33. Chuturgoon AA, Phulukdaree A, Moodley D. Fumonisin B1 modulates expression of human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b. Toxicol Lett 2014;227:50-5.
34. Chang I, Mitsui Y, Fukuhara S, Gill A, Wong DK, et al. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget 2015;6:7774-87.
35. Mao M, Wu Z, Chen J. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun 2016;478:649-55.
36. Leung T, Rajendran R, Singh S, Garva R, Krstic-Demonacos M, et al. Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells. Breast Cancer Res 2013;15:R107.
37. Daly AK. Genetic Polymorphisms Affecting Drug Metabolism. Recent Advances and Clinical Aspects. Adv Pharmacol 2012;63:137-67.
38. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, et al. Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 2010;79:1045-52.
39. Shukla U, Tumma N, Gratsch T, Dombkowski A, Novak RF. Insights into insulin-mediated regulation of CYP2E1: miR-132/-212 targeting of CYP2E1 and role of phosphatidylinositol 3-kinase, Akt (protein kinase B), mammalian target of rapamycin signaling in regulating miR-132/-212 and miR-122/-181a expression in pri. Drug Metab Dispos 2013;41:1769-77.
40. Miao L, Yao H, Li C, Pu M, Yao X, et al. A dual inhibition: MicroRNA-552 suppresses both transcription and translation of cytochrome P450 2E1. Biochim Biophys Acta - Gene Regul Mech 2016;1859:650-62.
41. Hu GX, Dai DP, Wang H, Huang XX, Zhou XY, et al. Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics 2017;18:369-79.
42. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009;37:2112-7.
43. Liu JE, Ren B, Tang L, Tang QJ, Liu XY, et al. The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin. Sci Rep 2016;6:26544.
44. Jones HM, Fang Z, Sun W, Clark LH, Stine JE, et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. Am J Cancer Res 2017;7:2478-90.
45. Duffel MW, Marshall AD, McPhie P, Sharma V, Jakoby WB. Enzymatic aspects of the phenol (aryl) sulfotransferases. Drug Metab Rev 2001;33:369-95.
46. Mercer KE, Apostolov EO, da Costa GG, Yu X, Lang P, et al. Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. Int J Mol Epidemiol Genet 2010;1:92-103.
47. Yu X, Dhakal IB, Beggs M, Edavana VK, Williams S, et al. Functional genetic variants in the 3’-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci 2010;118:391-403.
48. McLellan LI, Wolf CR. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat 1999;2:153-64.
49. Sawers L, Ferguson MJ, Ihrig BR, Young HC, Chakravarty P, et al. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer 2014;111:1150-8.
50. Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 2012;57:38-45.
51. Dluzen DF, Sutliff AK, Chen G, Watson CJW, Ishmael FT, et al. Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines. J Pharmacol Exp Ther 2016;359:182-93.
52. Margaillan G, Lévesque É, Guillemette C. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. J Steroid Biochem Mol Biol 2016;155:85-93.
53. Papageorgiou I, Court MH. Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach. Biochem Pharmacol 2017;137:93-106.
54. Wijayakumara DD, Mackenzie PI, McKinnon RA, Hu DG, Meech R. Regulation of UDP-glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in liver cancer cells. J Pharmacol Exp Ther 2017;361:386-97.
55. Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Therapeut 2014;141:92-116.
56. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
57. Armada A, Martins C, Spengler G, Molnar J, Amaral L, et al. Fluorimetric methods for analysis of permeability, drug transport kinetics, and inhibition of the ABCB1 membrane transporter. Methods Mol Biol 2016;1395:87-103.
58. Kathawala RJ, Gupta P, Ashby CR, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Update 2015;18:1-17.
59. Gomes BC, Rueff J, Rodrigues AS. MicroRNAs and cancer drug resistance. Methods Mol Biol 2016;1395:137-62.
60. Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol 2014;77:587-96.
61. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66.
62. Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer 2016;115:431-41.
63. Jiang B, Yan LJ, Wu Q. ABCB1 (C1236T) Polymorphism Affects P-Glycoprotein-Mediated Transport of Methotrexate, Doxorubicin, Actinomycin D, and Etoposide. DNA Cell Biol 2019;38:485-90.
64. Tecza K, Pamula-Pilat J, Lanuszewska J, Grzybowska E. Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 2016;7:66790-808.
65. Hill CR, Jamieson D, Thomas HD, Brown CDA, Boddy AV, et al. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochem Pharmacol 2013;85:29-37.
66. Nakanishi T, Menju T, Nishikawa S, Takahashi K, Miyata R, et al. The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer. Cancer Med 2018;7:408-19.
67. Gromicho M, Dinis J, Magalhães M, Fernandes AR, Tavares P, et al. Development of imatinib and dasatinib resistance: Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 2011;52:1980-90.
68. Wang J, Ye C, Liu J, Hu Y. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem Biophys Res Commun 2018;501:1034-40.
69. Lu C, Shan Z, Li C, Yang L. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother 2017;86:450-6.
70. Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother 2018;99:832-8.
71. Zhao Y, Qi X, Chen J, Wei W, Yu C, et al. The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Lett 2017;408:102-11.
72. Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, et al. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression. Cell Prolif 2017;50:e12341.
73. Ikemura K, Yamamoto M, Miyazaki S, Mizutani H, Iwamoto T, et al. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol 2013;83:399-405.
74. Wang H, Zhan M, Xu SW, Chen W, Long MM, et al. MiR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis 2017;8:e2770.
75. di Wu D, Li X song, Meng XN, Yan J, Zong Z hong. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumor Biol 2016;37:10499-506.
76. Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2012;29:2527-34.
77. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012;180:2490-503.
78. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008;7:2152-9.
79. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008;76:582-8.
80. Yi D, Xu L, Wang R, Lu X, Sang J. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int 2019;43:12-21.
81. Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, et al. Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. In: Mukhopadhyay P, editor. PLoS One 2013. p. e82062.
82. Li Y, Zhao L, Li N, Miao Y, Zhou H, Jia L. MiR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. Oncol Rep 2017;37:2193-200.
83. Zou Z, Zou R, Zong D, Shi Y, Chen J, et al. miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med 2017;21:1929-43.
84. Cole SPC. Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1 ): Past, Present, and Future. Annu Rev Pharmacol Toxicol 2014;54:95-117.
85. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011;278:3226-45.
86. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010;127:1785-94.
87. Liang Z, Wu H, Xia J, Li Y, Zhang Y, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010;79:817-24.
88. Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 2013;41:1744-51.
89. Zhan M, Zhao X, Wang H, Chen W, Xu S, et al. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumor Biol 2016;37:10553-62.
90. Gao M, Miao L, Liu M, Li C, Yu C, et al. MiR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget 2016;7:59714-26.
91. Pei K, Zhu JJ, Wang CE, Xie QL, Guo JY. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci 2016;20:4697-704.
92. Xu K, Liang X, Shen K, Cui D, Zheng Y, et al. miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J 2012;446:291-300.
93. Wu K, Yang Y, Zhao J, Zhao S. BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer Lett 2016;371:125-33.
94. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012;83:1084-103.
95. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JGM, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-36.
96. Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, et al. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res 2011;17:6510-21.
97. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, et al. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 2004;108:146-51.
98. Jiao X, Zhao L, Ma M, Bai X, He M, et al. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 2013;139:717-30.
99. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, et al. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 2011;81:783-92.
100. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009;75:1374-9.
101. Ma MT, He M, Wang Y, Jiao XY, Zhao L, et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 2013;339:107-15.
102. Chen B, Zhang D, Kuai J, Cheng M, Fang X, et al. Upregulation of mir-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. Tumor Biol 2017;39:1010428317715155.
103. Zhang L, Guo X, Zhang D, Fan Y, Qin L, et al. Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog 2017;56:2022-34.
104. Jia M, Wei Z, Liu P, Zhao X. Silencing of ABCG2 by microRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. J Korean Med Sci 2016;31:836-42.
